From Wikipedia, the free encyclopedia
Jump to: navigation, search
Systematic (IUPAC) name
Clinical data
25654-31-3 N
PubChem CID 5315659
ChemSpider 4474921 YesY
Chemical data
Formula C21H32O2
316.48 g/mol
 N (what is this?)  (verify)

Cannabigerol (CBG) is a non-psychoactive cannabinoid found in the Cannabis genus of plants. Cannabigerol is found in higher concentrations in hemp rather than in varieties of Cannabis cultivated for high tetrahydrocannabinol (THC) content and their corresponding psychoactive properties.[citation needed]

Cannabigerol has been found to act as a high affinity α2-adrenergic receptor agonist, moderate affinity 5-HT1A receptor antagonist, and low affinity CB1 receptor antagonist.[1] It also binds to the CB2 receptor, but whether it acts as an agonist or antagonist at this site is unknown.[1]


It has two E/Z isomers.


Cannabigerol has been shown to relieve interocular pressure, which may be of benefit in the treatment of glaucoma.[2][3] It can also be used to treat inflammatory bowel disease. [4]

Legal status[edit]

CBG is not scheduled by Convention on Psychotropic Substances.

United States[edit]

CBG is not scheduled at the federal level in the United States.[5]

See also[edit]


  1. ^ a b Cascio MG, Gauson LA, Stevenson LA, Ross RA, Pertwee R (December 2009). "Evidence that the plant cannabinoid cannabigerol is a highly potent alpha(2)-adrenoceptor agonist and moderately potent 5HT receptor antagonist". British Journal of Pharmacology 159 (1): 129–141. doi:10.1111/j.1476-5381.2009.00515.x. PMC 2823359. PMID 20002104. 
  2. ^ Colasanti, B. (1990). "A comparison of the ocular and central effects of delta 9-tetrahydrocannabinol and cannabigerol". Journal of ocular pharmacology 6 (4): 259–269. doi:10.1089/jop.1990.6.259. PMID 1965836.  edit
  3. ^ Colasanti, B.; Craig, C.; Allara, R. (1984). "Intraocular pressure, ocular toxicity and neurotoxicity after administration of cannabinol or cannabigerol". Experimental eye research 39 (3): 251–259. doi:10.1016/0014-4835(84)90013-7. PMID 6499952.  edit
  4. ^ "Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease.". Biochem Pharmacol 85 (9): 1306–16. May 2013. doi:10.1016/j.bcp.2013.01.017. PMID 23415610. 
  5. ^ §1308.11 Schedule I.